Nature, volume 583, issue 7815, pages 290-295

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto ¹

Young-Jun Park ²

Martina Beltramello ¹

Alexandra C Walls ²

M. Tortorici ^{2, 3}

Siro Bianchi ¹

Stefano Jaconi ¹

Katja Culap ¹

Fabrizia Zatta ¹

Anna De Marco ¹

Alessia Peter ¹

Barbara Guarino ¹

Roberto Spreafico ⁴

Elisabetta Cameroni ¹

James B. Case ⁵

Rita E. Chen ^{5, 6}

Colin Havenar Daughton ⁴

Gyorgy Snell ⁴

Amalio Telenti ⁴

Herbert W Virgin ⁴

Antonio Lanzavecchia ^{1, 7}

Michael S. Diamond ^{5, 6, 8}

Katja Fink ¹

David Veesler ²

Davide Corti ¹

Hide authors affiliations Show authors affiliations: 8 affiliations

Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland |

Department of Biochemistry, University of Washington, Seattle, USA |

Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France |

⁴

Vir Biotechnology, San Francisco, USA |

⁵

Department of Medicine, Washington University School of Medicine, St Louis, USA |

⁶

Department of Pathology and Immunology, Washington University School Of Medicine, St Louis, USA |

⁷

Institute for Research in Biomedicine, Università Della Svizzera Italiana, Bellinzona, Switzerland |

⁸

Department of Molecular Microbiology, Washington University School of Medicine, St Louis, USA |

Publication type: Journal Article

Publication date: 2020-05-18

Springer Nature

Journal: Nature

Quartile SCImago

Quartile WOS

Impact factor: 64.8

ISSN: 00280836, 14764687

DOI: 10.1038/s41586-020-2349-y

Copy DOI

Multidisciplinary

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease. The monoclonal antibody S309, identified from memory B cells of an individual infected with SARS-CoV in 2003, or antibody cocktails that contain this antibody potently neutralize SARS-CoV-2.

By date By citations

Top-30

Citations by journals

	5 10 15 20 25 30 35 40 45 50
Nature Communications	Nature Communications, 48, 2.83% Nature Communications 48 publications, 2.83%
Cell Reports	Cell Reports, 48, 2.83% Cell Reports 48 publications, 2.83%
Frontiers in Immunology	Frontiers in Immunology, 40, 2.36% Frontiers in Immunology 40 publications, 2.36%
Cell	Cell, 38, 2.24% Cell 38 publications, 2.24%
Viruses	Viruses, 34, 2.01% Viruses 34 publications, 2.01%
Nature	Nature, 33, 1.95% Nature 33 publications, 1.95%
Science	Science, 30, 1.77% Science 30 publications, 1.77%
iScience	iScience, 28, 1.65% iScience 28 publications, 1.65%
Immunity	Immunity, 21, 1.24% Immunity 21 publications, 1.24%
Cell Host and Microbe	Cell Host and Microbe, 21, 1.24% Cell Host and Microbe 21 publications, 1.24%
Vaccines	Vaccines, 19, 1.12% Vaccines 19 publications, 1.12%
PLoS Pathogens	PLoS Pathogens, 17, 1% PLoS Pathogens 17 publications, 1%
Signal Transduction and Targeted Therapy	Signal Transduction and Targeted Therapy, 17, 1% Signal Transduction and Targeted Therapy 17 publications, 1%
Scientific Reports	Scientific Reports, 16, 0.94% Scientific Reports 16 publications, 0.94%
Proceedings of the National Academy of Sciences of the United States of America	Proceedings of the National Academy of Sciences of the United States of America, 15, 0.88% Proceedings of the National Academy of Sciences of the United States of America 15 publications, 0.88%
Journal of Virology	Journal of Virology, 13, 0.77% Journal of Virology 13 publications, 0.77%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 12, 0.71% International Journal of Molecular Sciences 12 publications, 0.71%
Science Translational Medicine	Science Translational Medicine, 11, 0.65% Science Translational Medicine 11 publications, 0.65%
Science advances	Science advances, 11, 0.65% Science advances 11 publications, 0.65%
Cell Reports Medicine	Cell Reports Medicine, 10, 0.59% Cell Reports Medicine 10 publications, 0.59%
npj Vaccines	npj Vaccines, 9, 0.53% npj Vaccines 9 publications, 0.53%
Frontiers in Molecular Biosciences	Frontiers in Molecular Biosciences, 8, 0.47% Frontiers in Molecular Biosciences 8 publications, 0.47%
Frontiers in Microbiology	Frontiers in Microbiology, 8, 0.47% Frontiers in Microbiology 8 publications, 0.47%
Communications Biology	Communications Biology, 8, 0.47% Communications Biology 8 publications, 0.47%
Cell Research	Cell Research, 8, 0.47% Cell Research 8 publications, 0.47%
International Immunopharmacology	International Immunopharmacology, 8, 0.47% International Immunopharmacology 8 publications, 0.47%
Science immunology	Science immunology, 8, 0.47% Science immunology 8 publications, 0.47%
Nature Structural and Molecular Biology	Nature Structural and Molecular Biology, 7, 0.41% Nature Structural and Molecular Biology 7 publications, 0.41%
Cell Discovery	Cell Discovery, 7, 0.41% Cell Discovery 7 publications, 0.41%
	5 10 15 20 25 30 35 40 45 50

Citations by publishers

	50 100 150 200 250 300 350 400 450
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 428, 25.25% Cold Spring Harbor Laboratory 428 publications, 25.25%
Elsevier	Elsevier, 349, 20.59% Elsevier 349 publications, 20.59%
Springer Nature	Springer Nature, 283, 16.7% Springer Nature 283 publications, 16.7%
Multidisciplinary Digital Publishing Institute (MDPI)	Multidisciplinary Digital Publishing Institute (MDPI), 92, 5.43% Multidisciplinary Digital Publishing Institute (MDPI) 92 publications, 5.43%
Frontiers Media S.A.	Frontiers Media S.A., 78, 4.6% Frontiers Media S.A. 78 publications, 4.6%
Wiley	Wiley, 63, 3.72% Wiley 63 publications, 3.72%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 61, 3.6% American Association for the Advancement of Science (AAAS) 61 publications, 3.6%
American Chemical Society (ACS)	American Chemical Society (ACS), 45, 2.65% American Chemical Society (ACS) 45 publications, 2.65%
Taylor & Francis	Taylor & Francis, 33, 1.95% Taylor & Francis 33 publications, 1.95%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 31, 1.83% Public Library of Science (PLoS) 31 publications, 1.83%
Oxford University Press	Oxford University Press, 31, 1.83% Oxford University Press 31 publications, 1.83%
American Society for Microbiology	American Society for Microbiology, 27, 1.59% American Society for Microbiology 27 publications, 1.59%
Proceedings of the National Academy of Sciences (PNAS)	Proceedings of the National Academy of Sciences (PNAS), 15, 0.88% Proceedings of the National Academy of Sciences (PNAS) 15 publications, 0.88%
American Society for Clinical Investigation	American Society for Clinical Investigation, 10, 0.59% American Society for Clinical Investigation 10 publications, 0.59%
Rockefeller University Press	Rockefeller University Press, 9, 0.53% Rockefeller University Press 9 publications, 0.53%
Wolters Kluwer Health	Wolters Kluwer Health, 6, 0.35% Wolters Kluwer Health 6 publications, 0.35%
eLife Sciences Publications	eLife Sciences Publications, 6, 0.35% eLife Sciences Publications 6 publications, 0.35%
American Society for Biochemistry and Molecular Biology	American Society for Biochemistry and Molecular Biology, 6, 0.35% American Society for Biochemistry and Molecular Biology 6 publications, 0.35%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 6, 0.35% Royal Society of Chemistry (RSC) 6 publications, 0.35%
Dove Medical Press	Dove Medical Press, 6, 0.35% Dove Medical Press 6 publications, 0.35%
Future Medicine	Future Medicine, 5, 0.29% Future Medicine 5 publications, 0.29%
Pleiades Publishing	Pleiades Publishing, 5, 0.29% Pleiades Publishing 5 publications, 0.29%
SAGE	SAGE, 5, 0.29% SAGE 5 publications, 0.29%
KeAi Communications Co.	KeAi Communications Co., 4, 0.24% KeAi Communications Co. 4 publications, 0.24%
EMBO press	EMBO press, 4, 0.24% EMBO press 4 publications, 0.24%
Mary Ann Liebert	Mary Ann Liebert, 3, 0.18% Mary Ann Liebert 3 publications, 0.18%
The American Association of Immunologists	The American Association of Immunologists, 3, 0.18% The American Association of Immunologists 3 publications, 0.18%
Bentham Science	Bentham Science, 3, 0.18% Bentham Science 3 publications, 0.18%
Portland Press	Portland Press, 3, 0.18% Portland Press 3 publications, 0.18%
	50 100 150 200 250 300 350 400 450

We do not take into account publications without a DOI.
Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
Statistics recalculated weekly.

{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2020,2021,2022,2023,2024],"ids":[0,0,0,0,0],"codes":[0,0,0,0,0],"imageUrls":["","","","",""],"datasets":[{"label":"Citations number","data":[283,599,437,242,134],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["16.7","35.34","25.78","14.28","7.91"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Nature Communications","Cell Reports","Frontiers in Immunology","Cell","Viruses","Nature","Science","iScience","Immunity","Cell Host and Microbe","Vaccines","PLoS Pathogens","Signal Transduction and Targeted Therapy","Scientific Reports","Proceedings of the National Academy of Sciences of the United States of America","Journal of Virology","International Journal of Molecular Sciences","Science Translational Medicine","Science advances","Cell Reports Medicine","npj Vaccines","Frontiers in Molecular Biosciences","Frontiers in Microbiology","Communications Biology","Cell Research","International Immunopharmacology","Science immunology","Nature Structural and Molecular Biology","Cell Discovery"],"ids":[3231,9130,1699,16552,2455,14611,7711,6073,15890,22961,24868,5093,10186,13767,306,19580,14627,358,23003,27854,20541,3133,24403,11778,10892,11569,1356,13408,22751],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/s10mcsCV4OAUg9O2KrqOquQC0PhyLMI8hUUkuflM_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/mxFdPe9qujsfvfYfcN0QOclAiYORFb0xrRlwV8gs_medium.webp","\/storage\/images\/resized\/VPE7q24PXoHr5SS2SqfEgxccSMUxWLfZINOX60uo_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/s10mcsCV4OAUg9O2KrqOquQC0PhyLMI8hUUkuflM_medium.webp","\/storage\/images\/resized\/s10mcsCV4OAUg9O2KrqOquQC0PhyLMI8hUUkuflM_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/s10mcsCV4OAUg9O2KrqOquQC0PhyLMI8hUUkuflM_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp"],"datasets":[{"label":"","data":[48,48,40,38,34,33,30,28,21,21,19,17,17,16,15,13,12,11,11,10,9,8,8,8,8,8,8,7,7],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[2.83,2.83,2.36,2.24,2.01,1.95,1.77,1.65,1.24,1.24,1.12,1,1,0.94,0.88,0.77,0.71,0.65,0.65,0.59,0.53,0.47,0.47,0.47,0.47,0.47,0.47,0.41,0.41],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Cold Spring Harbor Laboratory","Elsevier","Springer Nature","Multidisciplinary Digital Publishing Institute (MDPI)","Frontiers Media S.A.","Wiley","American Association for the Advancement of Science (AAAS)","American Chemical Society (ACS)","Taylor & Francis","Public Library of Science (PLoS)","Oxford University Press","American Society for Microbiology","Proceedings of the National Academy of Sciences (PNAS)","American Society for Clinical Investigation","Rockefeller University Press","Wolters Kluwer Health","eLife Sciences Publications","American Society for Biochemistry and Molecular Biology","Royal Society of Chemistry (RSC)","Dove Medical Press","Future Medicine","Pleiades Publishing","SAGE","KeAi Communications Co.","EMBO press","Mary Ann Liebert","The American Association of Immunologists","Bentham Science","Portland Press"],"ids":[6909,17,8,202,208,11,189,40,18,344,19,142,162,564,22,32,6627,2090,123,417,6949,101,31,326,9415,230,7871,39,801],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/hg4jJjT8wVGtHstBCc0zk465Mg9pLx3G4odCDOqE_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/s10mcsCV4OAUg9O2KrqOquQC0PhyLMI8hUUkuflM_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/VPE7q24PXoHr5SS2SqfEgxccSMUxWLfZINOX60uo_medium.webp","\/storage\/images\/resized\/mxFdPe9qujsfvfYfcN0QOclAiYORFb0xrRlwV8gs_medium.webp","\/storage\/images\/resized\/aFa86lAy63Pq5tYKiOsH017UsgJA6uk6ed66C0Ns_medium.webp","\/storage\/images\/resized\/lEA1FyUnFAZR1DchuczZi5bjAixG3TNeWVz6oF4R_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/eIZgkq1MRZyJ3hBkdupnUUv7wgB6zCl9D99SlPN5_medium.webp","\/storage\/images\/resized\/OuA6WPZekwEiUM99mP2pSqj4yHPxHezM6xgLhAjO_medium.webp","\/storage\/images\/resized\/leiAYcRDGTSl5B1eCnwpSGqmDEUEfDPPoYisFGhT_medium.webp","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/oZgeErrVFhuDksyqFURLvYS1wtVSBWczh001igGo_medium.webp","\/storage\/images\/resized\/ruydfaB80LDjlkYqsfOeUAZohOIODyq7bQzis5O7_medium.webp","\/storage\/images\/resized\/jeWDR7NTA9Ab5MVz8Uqjl2RPCndzFjSyl0FaRAHg_medium.webp","\/storage\/images\/resized\/1UiI5HycPsvulDeXOySNp0OuaMMmIKfPnsdKPyH0_medium.webp","\/storage\/images\/resized\/Zy5YST233rzRbZP24I24MzZm64hz20ZV9qQopmMn_medium.webp","\/storage\/images\/resized\/Teo7jjEEA71rw8mjlFC8lDbYotZhhtZbL0J9gPs2_medium.webp","\/storage\/images\/resized\/doUaFUZdxUEQjLi1TwZjGHi8HXYNWWSk04dSC6Xh_medium.webp","\/storage\/images\/resized\/nUqNrP9GnM1t0BrAIXp1LBodjU8aIJ2Fk4pLfGhZ_medium.webp"],"datasets":[{"label":"","data":[428,349,283,92,78,63,61,45,33,31,31,27,15,10,9,6,6,6,6,6,5,5,5,4,4,3,3,3,3],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[25.25,20.59,16.7,5.43,4.6,3.72,3.6,2.65,1.95,1.83,1.83,1.59,0.88,0.59,0.53,0.35,0.35,0.35,0.35,0.35,0.29,0.29,0.29,0.24,0.24,0.18,0.18,0.18,0.18],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"yearsCitationsQuartiles":{"type":"bar","data":{"show":true,"labels":[2020,2021,2022,2023,2024],"ids":[],"codes":[],"imageUrls":[],"datasets":[{"label":"Q4","backgroundColor":"rgb(221,90,78)","data":[1,3,3,2,4],"percentage":["0.06","0.18","0.18","0.12","0.24"]},{"label":"Q3","backgroundColor":"rgb(251, 163,83)","data":[3,7,5,6,2],"percentage":["0.18","0.41","0.29","0.35","0.12"]},{"label":"Q2","backgroundColor":"rgb(232, 213, 89)","data":[11,33,17,17,8],"percentage":["0.65","1.95","1","1","0.47"]},{"label":"Q1","backgroundColor":"rgb(164, 207, 99)","data":[148,373,294,158,90],"percentage":["8.73","22.01","17.35","9.32","5.31"]},{"label":"Quartile not defined","backgroundColor":"#E5E7EB","data":[120,183,118,59,30],"percentage":["7.08","10.8","6.96","3.48","1.77"]}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations quartiles by SCImago per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"yearsCitationsQuartilesWs":{"type":"bar","data":{"show":true,"labels":[2020,2021,2022,2023,2024],"ids":[],"codes":[],"imageUrls":[],"datasets":[{"label":"Q4","backgroundColor":"rgb(221,90,78)","data":[3,5,4,4,0],"percentage":["0.18","0.29","0.24","0.24","0"]},{"label":"Q3","backgroundColor":"rgb(251, 163,83)","data":[3,24,8,6,10],"percentage":["0.18","1.42","0.47","0.35","0.59"]},{"label":"Q2","backgroundColor":"rgb(232, 213, 89)","data":[28,85,57,44,13],"percentage":["1.65","5.01","3.36","2.6","0.77"]},{"label":"Q1","backgroundColor":"rgb(164, 207, 99)","data":[118,283,238,123,75],"percentage":["6.96","16.7","14.04","7.26","4.42"]},{"label":"Quartile not defined","backgroundColor":"#E5E7EB","data":[131,202,130,65,36],"percentage":["7.73","11.92","7.67","3.83","2.12"]}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations quartiles by WoS per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Pinto D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody // Nature. 2020. Vol. 583. No. 7815. pp. 290-295.

GOST all authors (up to 50) Copy

Pinto D., Park Y., Beltramello M., Walls A. C., Tortorici M., Bianchi S., Jaconi S., Culap K., Zatta F., De Marco A., Peter A., Guarino B., Spreafico R., Cameroni E., Case J. B., Chen R. E., Havenar Daughton C., Snell G., Telenti A., Virgin H. W., Lanzavecchia A., Diamond M., Fink K., Veesler D., Corti D. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody // Nature. 2020. Vol. 583. No. 7815. pp. 290-295.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1038/s41586-020-2349-y

UR - https://doi.org/10.1038/s41586-020-2349-y

TI - Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

T2 - Nature

AU - Pinto, Dora

AU - Park, Young-Jun

AU - Beltramello, Martina

AU - Walls, Alexandra C

AU - Tortorici, M.

AU - Bianchi, Siro

AU - Jaconi, Stefano

AU - Culap, Katja

AU - Zatta, Fabrizia

AU - De Marco, Anna

AU - Peter, Alessia

AU - Guarino, Barbara

AU - Spreafico, Roberto

AU - Cameroni, Elisabetta

AU - Case, James B.

AU - Chen, Rita E.

AU - Havenar Daughton, Colin

AU - Snell, Gyorgy

AU - Telenti, Amalio

AU - Virgin, Herbert W

AU - Lanzavecchia, Antonio

AU - Diamond, Michael S.

AU - Fink, Katja

AU - Veesler, David

AU - Corti, Davide

PY - 2020

DA - 2020/05/18 00:00:00

PB - Springer Nature

SP - 290-295

IS - 7815

VL - 583

SN - 0028-0836

SN - 1476-4687

ER -

BibTex |

Cite this

BibTex Copy

@article{2020_Pinto,

author = {Dora Pinto and Young-Jun Park and Martina Beltramello and Alexandra C Walls and M. Tortorici and Siro Bianchi and Stefano Jaconi and Katja Culap and Fabrizia Zatta and Anna De Marco and Alessia Peter and Barbara Guarino and Roberto Spreafico and Elisabetta Cameroni and James B. Case and Rita E. Chen and Colin Havenar Daughton and Gyorgy Snell and Amalio Telenti and Herbert W Virgin and Antonio Lanzavecchia and Michael S. Diamond and Katja Fink and David Veesler and Davide Corti},

title = {Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody},

journal = {Nature},

year = {2020},

volume = {583},

publisher = {Springer Nature},

month = {may},

url = {https://doi.org/10.1038/s41586-020-2349-y},

number = {7815},

pages = {290--295},

doi = {10.1038/s41586-020-2349-y}

}

MLA

Cite this

MLA Copy

Pinto, Dora, et al. “Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.” Nature, vol. 583, no. 7815, May. 2020, pp. 290-295. https://doi.org/10.1038/s41586-020-2349-y.

Found error?

Publisher

Springer Nature

Journal

Nature

Quartile SCImago

Quartile WOS

Impact factor

64.8

ISSN

00280836 (Print)
14764687 (Electronic)